Nanobiotix Launches Curadigm Facility with Nanoprimer Technology in France and the US

 Nanobiotix Launches Curadigm Facility with Nanoprimer Technology in France and the US

Nanobiotix Launches Curadigm Facility with Nanoprimer Technology in France and the US

Shots:

  • Nanobiotix launches a new subsidiary, Curadigm along with its Nanoprimer technology to reshape the balance b/w bioavailability, toxicity, and efficacy in the healthcare system in France & the US
  • Nanobiotix will remain focus on its lead candidate NBTXR3 to expand radiotherapy benefits and its Immuno-Oncology program to innovate cancer immunotherapies and has also received marketing approval in Europe
  • Curadigm technology increases the efficacy at current doses, decreases toxicity & cost, allowing to utilize new approaches for drug designing and is presented at AACR 2019

Click here to read full press release/ article | Ref: GlobeNewsWire | Image: My French Startup

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post